Clinical Research

Glaukos (GLK-401-01)

Glaucoma surgical device study of the iStent Infinite
A Prospective, Multicenter Study of the Glaukos iStent Infinite Trabecular Micro-Bypass System Model IS3 in Subjects with Mild to Moderate Primary Open-Angle Glaucoma

• Physician: Anup Khatana, MD
• Location: 1945 CEI Drive, Cincinnati, OH 45242
• Coordinator: Lee Stokes, (513) 569-3213

Ivantis (CP 18-001)

Glaucoma surgical device post market study of the Hydrus microstent with cataract surgery
The Hydrus Microstent New Enrollment Post-Approval Study: A Prospective, Non-randomized, Multicenter, Single Arm, Clinical Trial (CONFIRM)

• Physician: Edward Meier, MD
• Location: 6150 Radio Way, Mason, OH 45040
• Coordinator: Tina Winward, (513) 770-4020 ext.3324

iStar Medical (Star-V)

Glaucoma surgical device study of the MINIject CS627
A Prospective, Multicenter Masked Clinical Trial to Evaluate the Safety and Effectiveness of the MINIject CS627 Implant in Subjects with Open Angle Glaucoma

• Physician: Edward Meier, MD
• Location: 6150 Radio Way, Mason, OH 45040
• Coordinator: Tina Winward, (513) 770-4020 ext.3324

Alcon Research (ILQ137-C002)

Contralateral Study of Clareon PanOptix Pro vs. Clareon PanOptix

• Physician: Michael Snyder, MD
• Location: 1945 CEI Drive, Cincinnati, OH 45242
• Coordinator: Grace Bruns, (513) 569-3549

Aurion Biotech (ABA-1)

Intracameral injection for certain corneal dystrophies
A Phase 1/2 Multi-Center, Randomized, Double-Masked, Prospective, Parallel-Arm Study of AURN001 in Subjects with Corneal Edema Secondary to Corneal Endothelial Dysfunction (CLARA)

• Physician: Michael Nordlund, MD
• Location: 1945 CEI Drive, Cincinnati, OH 45242
• Coordinator: Lee Stokes (513) 569-3213

Epion Therapeutics (CXL-006-A)

Corneal Treatment for Keratoconus
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-Linking in Subjects 8 to 45 Years of Age with Keratoconus

• Physician: Adam Kaufman, MD
• Location: 1945 CEI Drive, Cincinnati, OH 45242
• Coordinator: Meagana Wilkins, (513) 569-3285

Kowa Research (K-321-303)

Eye Drop Study for Corneal Treatment of Fuch’s Dystrophy after Cataract Surgery
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration with Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Efficacy and Safety of Ripasudil (K-321) Eye Drops after Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

• Physician: Michael Nordlund, MD
• Location: 1945 CEI Drive, Cincinnati, OH 45242
• Coordinator: Melissa Schoonover, (513) 569-3660

Not Currently Enrolling

RegenxBio-Ascent/Atmosphere (RGX-314-3101/2104)

Gene Therapy surgical trial for Wet AMD
A Randomized, partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with AMD.

• Physician: Robert Sisk, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Noah Wendt, (513) 569-3479

Opregen (GR44251)

Gene Therapy Surgical trial for dry AMD
A Phase IIa, Open-Label, Single-Arm, Multicenter Study to Optimize Subretinal Surgical Delivery of Opregen in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

• Physician: Christopher Riemann, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Ryanne Sullivan, (513) 569-3170

Genentech (ML43000 Belvedere)

Surgical trial for wet AMD using the port delivery system
A Phase IIIb/IV, Multicenter, Visual Assessor Masked Study of the Efficacy and Safety of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Intravitreal Agents Other than Ranibizumab.

• Physician: Lucas Lindsell, OD, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Emily Collier, (513) 569-3178

Janssen (81201887MDG2001)

Injection trial for dry AMD 
A Phase 2/3, Randomized, Double-Masked, Multicenter, Dose-Ranging, Sham-Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) (PARASOL)

• Physician: Lucas Lindsell, OD, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Ryanne Sullivan, (513) 569-3170

Beacon Therapeutics (RPGR-001 Dawn)

Gene Therapy Surgical Trial for x-linked Retinitis Pigmentosa
A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-Center Study Comparing Two Doses of AGTC-501 in Male Participants with X-Linked Retinitis Pigmentosa

• Physician: Robert Sisk, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Noah Wendt, (513) 569-3479

Beacon Therapeutics (RPGR-002 Vista)

Gene Therapy Surgical Trial for x-linked Retinitis Pigmentosa
A Phase 2/3 Randomized, Controlled, Masked, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), compared to an Untreated Control Group in Male Subjects with X-Linked Retinitis Pigmentosa Confirmed by a Pathogenic Variant in the RPGR Gene

• Physician: Robert Sisk, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Noah Wendt, (513) 569-3479

Ascidian (ACDN-01-001)

Gene Therapy Surgical Trial for Stargardt’s Dystrophy
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinally Delivered ACDN-01 in Participants with ABCA4-related Retinopathy (Stargardt’s/Rod-Cone Dystrophy)

• Physician: Robert Sisk, MD
• Location: 9997 Carver Road, Cincinnati, OH 45242
• Coordinator: Ryanne Sullivan, (513) 569-3170